Influx Healthtech Limited
NNSE:INFLUX258.10
INR
-4.55
(-1.73%)
ISIN
INE0MYZ01012
Return %
Stock
S&P 500
1Y
48.04
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Munir Abdul Ganee Chandniwala
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Mumbai India
- IPO Date
- Jun 25, 2025
- Website
- influxhealthtech.com
- Similar Companies
- Business
- Influx Healthtech Limited is an India-based contract development and manufacturing organization (CDMO) that provides end-to-end formulation development, manufacturing, and packaging services for the healthcare, wellness, personal care, and animal nutrition sectors. Headquartered in Mumbai, Maharashtra, and incorporated in 2020 with operational origins dating back to 2003, the company operates multi-dosage manufacturing facilities in Palghar, Maharashtra, compliant with Good Manufacturing Practice (GMP), HACCP, ISO 22000, ISO 14001, and Halal certifications. Influx Healthtech functions as a business-to-business (B2B) manufacturing partner for over 600 commercial clients, including pharmaceutical corporations, wellness enterprises, direct-to-consumer brands, and retail marketers in domestic and emerging overseas markets. The company provides a comprehensive product and service portfolio organized into five primary divisions: Nutraceuticals and Dietary Supplements, including hard gelatin and vegetarian capsules, sustained-release and chewable tablets, effervescent formulations, protein powders, oral liquids, softgels, gummies, and nutritional bars; Ayurvedic and Herbal Preparations, including herbal tonics, herbal extracts, medicated oils, digestive syrups, and immunity-support powders; Cosmetics and Dermatological Care, encompassing skin serums, anti-aging creams, lotions, facial cleansers, sunscreens, shampoos, hair oils, and topical ointments; Veterinary Formulations, comprising animal feed supplements, calcium suspensions, liver stimulants, veterinary boluses, and nutritional additives for livestock and pets; and Home Care Products, consisting of surface disinfectants, floor cleaners, and liquid detergents. In recent corporate developments, Influx Healthtech converted from a private limited company into a public limited company and completed an Initial Public Offering (IPO) on the National Stock Exchange of India (NSE Emerge platform under the symbol INFLUX) in June 2025, raising approximately INR 58.57 crore. The company is deploying the net issue proceeds to finance major capital expenditures, which include the commissioning of dedicated manufacturing facilities for its Nutraceutical and Veterinary Food divisions, the installation of advanced machinery for its Homecare and Cosmetic lines, and the expansion of international merchant export channels across Africa and Asia.